A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer

Trial Profile

A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene galvacirepvec; Rilimogene glafolivec
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top